RPTX Repare Therapeutics
- 3.550
- +0.020+0.57%
- 3.550
- 0.0000.00%
Repare Therapeutics News
Repare Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Repare Therapeutics Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
It's been a good week for Repare Therapeutics Inc. (NASDAQ:RPTX) shareholders, because the company has just released its latest first-quarter results, and the shares gained 8.7% to US$3.64. Reve
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estim
Repare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue Beats
By Chris Wack Repare Therapeutics shares were up 17% to $3.85 after the company reported first-quarter earnings that beat analysts' expectations. The company reported quarterly earnings of $13 milli
Repare Therapeutics Shares Are Trading Higher Following Better-than-expected Q1 Financial Results.
Repare Therapeutics Shares Are Trading Higher Following Better-than-expected Q1 Financial Results.
Small Cap Bid Up Following Key Q1 Earnings Beat
Repare Therapeutics RPTX Earnings; Enveric ENVB Patent Licensing
Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of RingCentral, Inc. (NYSE:RNG) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.RingCentr
Top Premarket Gainers
Innodata (INOD) shares rose 23% Wednesday premarket after the company reported improved Q1 results. Repare Therapeutics (RPTX) shares increased 21% after the company swung to Q1 profit amid higher rev
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Repare Therapeutics (RPTX) and Penumbra (PEN)
Repare Therapeutics (RPTX) Gets a Buy From Piper Sandler
Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue
07:07 AM EDT, 05/08/2024 (MT Newswires) -- Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue Price: 3.8600, Change: +0.58, Percent Change: +
Analysts' Opinions Are Mixed on These Healthcare Stocks: Repare Therapeutics (RPTX) and Demant (OtherWILLF)
Repare Therapeutics Advances Oncology Trials
Repare Therapeutics | 10-Q: Quarterly report
Press Release: Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
Repare Therapeutics 1Q EPS 30c >RPTX
Repare Therapeutics 1Q EPS 30c >RPTX
Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123
Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
Debiopharm (), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. ("Repare")
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 32% Plummet
Unfortunately for some shareholders, the Repare Therapeutics Inc. (NASDAQ:RPTX) share price has dived 32% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twe
Analysis
Price Target
No Data
